<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.114211</article-id><article-id pub-id-type="publisher-id">ACM-41498</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210400000_21855785.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  球囊扩张支架与自膨式支架治疗侧支循环欠佳的症状性颅内动脉狭窄的临床研究
  Balloon-Mounted Stent versus Self-Expanding Stent for Symptomatic Intracranial Artery Stenosis Combined with Poor Collateral Circulation
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>丁</surname><given-names>鸿斐</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>滕</surname><given-names>文慧</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>付</surname><given-names>蕾</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>贤军</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>荣</surname><given-names>婷</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姜</surname><given-names>英</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>勇</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>乃东</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院神经介入科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>04</month><year>2021</year></pub-date><volume>11</volume><issue>04</issue><fpage>1473</fpage><lpage>1481</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：比较球囊扩张支架与自膨式支架治疗侧支循环欠佳的症状性颅内动脉狭窄患者1年的临床疗效。方法：收集中国20家医院2013年9月至2015年1月接受球囊扩张支架或自膨式支架的258名症状性颅内动脉狭窄合并侧支循环不良患者为研究对象，对患者基线特征及临床疗效进行评估。结果：总体平均狭窄程度由支架植入前的83.73 &#177; 10.40%降至支架植入后的8.5 &#177; 7.96%。自膨式支架治疗的患者接受全身麻醉的比例高于球囊扩张支架治疗的患者(81.5% VS 62.7%, P = 0.001)，且手术时间更长(93.53 &#177; 24.11 min VS 68.09 &#177; 16.74 min, P &lt; 0.001)。使用自膨式支架治疗的患者需要更长和更大直径的支架(分别为14.44 &#177; 3.09 mm VS 9.67 &#177; 2.57 mm，P &lt; 0.001，3.06 &#177; 0.47 mm VS 2.69 &#177; 0.27 mm，P &lt; 0.001)。自膨式支架患者的残余狭窄率高于球囊扩张支架患者(11.36 &#177; 8.26% VS 5.99 &#177; 6.48%，P &lt; 0.001)，两组中使用自膨式支架的患者再狭窄发生率高(11/124 VS 21/112，P=0.027)，且再狭窄程度也较球囊扩张支架高(36.2 &#177; 18.33 VS 48.5 &#177; 24.51%, P &lt; 0.001)。1年随访期间，两组出现缺血性卒中、出血性卒中、短暂性脑缺血发作、死亡的发生率无显著差异(分别是P = 0.722、0.105、0.725、1.000)。结论：对于严重颅内动脉狭窄且合并侧支循环不良的患者，进行支架植入术相对安全。球囊扩张支架较自膨式支架的手术时间更短，发生再狭窄的机率及再狭窄程度更低，但两者1年随访结局无明显差异。
    Objective: To compare the 1-year clinical outcome of balloon-mounted stent versus self-expanding stent in the treatment of symptomatic intracranial artery stenosis combined with poor collateral circulation. Method: A total of 258 patients with symptomatic intracranial artery stenosis combined with poor collateral circulation were enrolled in the study. Balloon-mounted stent and self-expanding stent were selected according to the vascular conditions of the patients, then the baseline characteristics and clinical outcome of the patients were compared. Results: The overall mean degree of stenosis decreased from 83.73 &#177; 10.40% to 8.5 &#177; 7.96%. Patients treated with self-expanding stent were more likely to receive general anesthesia (81.5% vs 62.7%, P = 0.001), and the operation time was longer than balloon-mounted stent (93.53 &#177; 24.11 min vs 68.09 &#177; 16.74 min, P &lt; 0.001). Patients treated with self-expanding stent need longer and larger diameter stents than balloon-mounted stent (14.44 &#177; 3.09 mm vs 9.67 &#177; 2.57 mm, P &lt; 0.001, 3.06 &#177; 0.47 mm vs 2.69 &#177; 0.27 mm, respectively, P &lt; 0.001), the residual stenosis rate of patients with self-expanding stent was higher than patients treated with balloon-mounted stent (11.36 &#177; 8.26% vs 5.99 &#177; 6.48%, P &lt; 0.001), and the restenosis rate of patients with self-expanding stent was higher than that patients treated with balloon-mounted stent (11/124 vs 21/112, P = 0.027), the restenosis degree was also higher than the patients treated with balloon-mounted stent (36.2 &#177; 18.33 vs 48.5 &#177; 24.51%, P &lt; 0.001). The rates of stroke, transient ischemic attack or death at 1-year follow-up were not significantly different between two groups (P = 0.722, 0.105, 0.725 and 1.000, respectively). Conclusions: For patients with severe intracranial artery stenosis combined with poor collateral circulation, stent implantation can be performed safely. Compared with self-expanding stent, the operation time of balloon expanding stent is shorter, and the probability and degree of restenosis are lower, but there is not any significant difference in 1-year follow-up results between the 2 groups. 
  
 
</p></abstract><kwd-group><kwd>颅内动脉粥样硬化，颅内动脉狭窄，血管成形术，支架, Intracranial Atherosclerosis</kwd><kwd> Intracranial Arterial Stenosis</kwd><kwd> Angioplasty</kwd><kwd> Stent</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：比较球囊扩张支架与自膨式支架治疗侧支循环欠佳的症状性颅内动脉狭窄患者1年的临床疗效。方法：收集中国20家医院2013年9月至2015年1月接受球囊扩张支架或自膨式支架的258名症状性颅内动脉狭窄合并侧支循环不良患者为研究对象，对患者基线特征及临床疗效进行评估。结果：总体平均狭窄程度由支架植入前的83.73 &#177; 10.40%降至支架植入后的8.5 &#177; 7.96%。自膨式支架治疗的患者接受全身麻醉的比例高于球囊扩张支架治疗的患者(81.5% VS 62.7%, P = 0.001)，且手术时间更长(93.53 &#177; 24.11 min VS 68.09 &#177; 16.74 min, P &lt; 0.001)。使用自膨式支架治疗的患者需要更长和更大直径的支架(分别为14.44 &#177; 3.09 mm VS 9.67 &#177; 2.57 mm，P &lt; 0.001，3.06 &#177; 0.47 mm VS 2.69 &#177; 0.27 mm，P &lt; 0.001)。自膨式支架患者的残余狭窄率高于球囊扩张支架患者(11.36 &#177; 8.26% VS 5.99 &#177; 6.48%，P &lt; 0.001)，两组中使用自膨式支架的患者再狭窄发生率高(11/124 VS 21/112，P=0.027)，且再狭窄程度也较球囊扩张支架高(36.2 &#177; 18.33 VS 48.5 &#177; 24.51%, P &lt; 0.001)。1年随访期间，两组出现缺血性卒中、出血性卒中、短暂性脑缺血发作、死亡的发生率无显著差异(分别是P = 0.722、0.105、0.725、1.000)。结论：对于严重颅内动脉狭窄且合并侧支循环不良的患者，进行支架植入术相对安全。球囊扩张支架较自膨式支架的手术时间更短，发生再狭窄的机率及再狭窄程度更低，但两者1年随访结局无明显差异。</p></sec><sec id="s2"><title>关键词</title><p>颅内动脉粥样硬化，颅内动脉狭窄，血管成形术，支架</p></sec><sec id="s3"><title>Balloon-Mounted Stent versus Self-Expanding Stent for Symptomatic Intracranial Artery Stenosis Combined with Poor Collateral Circulation</title><p>Hongfei Ding, Wenhui Teng, Lei Fu, Xianjun Zhang, Ting Rong, Ying Jiang, Yong Zhang, Naidong Wang<sup>*</sup></p><p>Department of Neurology and Interventional Neurology, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/4-1572088x5_hanspub.png" /></p><p>Received: Mar. 6<sup>th</sup>, 2021; accepted: Mar. 30<sup>th</sup>, 2021; published: Apr. 9<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/4-1572088x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To compare the 1-year clinical outcome of balloon-mounted stent versus self-expanding stent in the treatment of symptomatic intracranial artery stenosis combined with poor collateral circulation. Method: A total of 258 patients with symptomatic intracranial artery stenosis combined with poor collateral circulation were enrolled in the study. Balloon-mounted stent and self-expanding stent were selected according to the vascular conditions of the patients, then the baseline characteristics and clinical outcome of the patients were compared. Results: The overall mean degree of stenosis decreased from 83.73 &#177; 10.40% to 8.5 &#177; 7.96%. Patients treated with self-expanding stent were more likely to receive general anesthesia (81.5% vs 62.7%, P = 0.001), and the operation time was longer than balloon-mounted stent (93.53 &#177; 24.11 min vs 68.09 &#177; 16.74 min, P &lt; 0.001). Patients treated with self-expanding stent need longer and larger diameter stents than balloon-mounted stent (14.44 &#177; 3.09 mm vs 9.67 &#177; 2.57 mm, P &lt; 0.001, 3.06 &#177; 0.47 mm vs 2.69 &#177; 0.27 mm, respectively, P &lt; 0.001), the residual stenosis rate of patients with self-expanding stent was higher than patients treated with balloon-mounted stent (11.36 &#177; 8.26% vs 5.99 &#177; 6.48%, P &lt; 0.001), and the restenosis rate of patients with self-expanding stent was higher than that patients treated with balloon-mounted stent (11/124 vs 21/112, P = 0.027), the restenosis degree was also higher than the patients treated with balloon-mounted stent (36.2 &#177; 18.33 vs 48.5 &#177; 24.51%, P &lt; 0.001). The rates of stroke, transient ischemic attack or death at 1-year follow-up were not significantly different between two groups (P = 0.722, 0.105, 0.725 and 1.000, respectively). Conclusions: For patients with severe intracranial artery stenosis combined with poor collateral circulation, stent implantation can be performed safely. Compared with self-expanding stent, the operation time of balloon expanding stent is shorter, and the probability and degree of restenosis are lower, but there is not any significant difference in 1-year follow-up results between the 2 groups.</p><p>Keywords:Intracranial Atherosclerosis, Intracranial Arterial Stenosis, Angioplasty, Stent</p><disp-formula id="hanspub.41498-formula16"><graphic xlink:href="//html.hanspub.org/file/4-1572088x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/4-1572088x8_hanspub.png" /> <img src="//html.hanspub.org/file/4-1572088x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 前言</title><p>2019年在柳叶刀杂志发表的中国最新死因调查发现，卒中高居榜首 [<xref ref-type="bibr" rid="hanspub.41498-ref1">1</xref>]，导致缺血性脑卒中的重要原因之一即颅内动脉粥样硬化性狭窄(Intracraninal atherosclerotic stenosis, ICAS) [<xref ref-type="bibr" rid="hanspub.41498-ref2">2</xref>]，2005年WASID试验发现对于颅内动脉狭窄程度达70%的患者，即使行积极的内科保守药物治疗如抗血小板、调脂等，2年内再发卒中发生率仍高达20%以上 [<xref ref-type="bibr" rid="hanspub.41498-ref3">3</xref>]。近年来，国内外多项研究表明血管内支架植入术相对安全，已成为治疗重度颅内动脉粥样硬化的重要治疗手段 [<xref ref-type="bibr" rid="hanspub.41498-ref4">4</xref>] - [<xref ref-type="bibr" rid="hanspub.41498-ref9">9</xref>]。</p><p>临床中常用的颅内支架包括Apollo球囊扩张支架和Wingspan 自膨式支架，迄今为止，比较球囊扩张支架与自膨式支架治疗重度颅内动脉粥样硬化疗效的研究较为缺乏。本研究作为前瞻性单臂多中心临床研究，比较了接受球囊扩张支架治疗与自膨式支架治疗的颅内动脉粥样硬化性狭窄患者预后的差异，为将来血管内支架植入术提供依据。</p></sec><sec id="s6"><title>2. 材料及方法</title><sec id="s6_1"><title>2.1. 研究对象与方法</title>研究对象<p>收集青岛大学附属医院等20家医院2013年9月至2015年1月接受球囊扩张支架或自膨式支架的颅内动脉重度狭窄合并侧枝循环不良患者。</p><p>1、入组标准</p><p>1) 年龄18~85岁；2) 根据血管造影术(Digital subtraction angiography, DSA)测量责任血管狭窄率70%~99%；3) 临床存在缺血性脑血管病症状，末次症状发生在90天内；4) 靶血管区存在血流灌注不足；5) 患者及家属均同意手术并签署知情同意书。在血管内治疗前14天内，根据以下任何一种方法对靶血管区进行血流动力学评估：1) 灌注计算机断层扫描(CTP)示靶血管区脑血流较对侧减少30%；2) 美国介入和治疗神经放射学学会/介入放射学学会(American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology collateral vessel grading system, ASTIN/SRI)侧支循环评估系统评分 &lt; 3分；3) 单光子发射CT扫描或磁共振成像(MRI)血流动力学示低灌注改变；4) 经颅多普勒超声示收缩期峰值速度 ≥ 200 cm/s，侧支血管 ≤ 1支。</p><p>2、排除标准</p><p>1) 近3周出现急性脑梗死；2) 病变血管严重迂曲，长度大于15毫米，血管直径小于2 mm；3) 高分辨MRI证实非颅内动脉粥样硬化性病变；4) 合并颅内动脉瘤、颅内肿瘤、动静脉畸形；5) 栓塞导致急性动脉闭塞的患者；6) 基线改良Rankin评分大于3分。</p></sec><sec id="s6_2"><title>2.2. 研究方法</title><sec id="s6_2_1"><title>2.2.1. 支架类型选择</title><p>支架类型由手术者根据其个人经验和病变血管情况进行选择。通常选择Apollo (Microport)球囊扩张支架治疗Mori A型病变或动脉路径较直的患者，对于路径迂曲或Mori C型病变或近端/远端直径之间显著不匹配的病变的患者，首选球囊预扩张并同时放置自膨式支架(Wingspan , Boston Scientific)治疗。</p></sec><sec id="s6_2_2"><title>2.2.2. 术前管理及手术方法</title><p>术前给予至少5天阿司匹林(100毫克/天)联合氯吡格雷(75毫克/天)双联抗血小板，或在术前临时口服氯吡格雷300毫克。麻醉方式根据手术者的经验和患者情况决定，手术全程肝素化。用Seldinger穿刺法穿刺右股动脉，将导管(Cordis Corporation, Miami Lakes, FL, USA)推入颈内动脉或椎动脉，微导丝(Transend, Boston Scientific, California)通过病变位置，将球囊扩张支架跨狭窄段放置，自膨式支架通过Gateway球囊预扩张继而放入支架，利用血管造影术复查即刻结果。术后24小时内复查颅脑CT，排除颅内出血等并发症。术后皮下注射低分子肝素(Sanof Winthrop Industry)，持续3天。</p></sec><sec id="s6_2_3"><title>2.2.3. 术后管理及随访</title><p>患者出院后均执行术前双抗方案3个月(阿司匹林100 mg/d联合氯吡格雷75 mg/d)，后需终身服用阿司匹林100 mg/d，保持健康的生活方式。实施积极的药物治疗以达到以下目标：合并高血压患者，积极平稳控制血压，收缩压 &lt; 140 mmHg，合并糖尿病患者收缩压 &lt; 130 mmHg，低密度脂蛋白 &lt; 70 mg/dl (1.81 mmol/L)或至少降低50% [<xref ref-type="bibr" rid="hanspub.41498-ref10">10</xref>]。由1~2名受过专项训练的专业神经科医生分别在在受试者术后1月、3月、6月、1年进行随访，随访期间，对出现类似神经系统并发症的患者，需进行颅脑MRA或CTA等明确原因，1年后对所有随访患者复查颅脑DSA或CTA。</p></sec><sec id="s6_2_4"><title>2.2.4. 统计分析方法</title><p>连续变量采用标准差或用四分位数间距表示平均值或中位数，分类变量用频率来表示。两组间连续变量的差异采用t检验或秩和检验进行检验，分类变量则采用卡方检验或Fisher确切检验法进行检验，计算并记录准确的P值，P &lt; 0.05表示具有统计学意义。统计分析采用SPSS 22.0软件。</p></sec></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 患者特征</title><p>纳入试验的受试者共258例，男性197例，女性61例，平均年龄为57.9 &#177; 9.28岁，缺血性卒中141例(54.7%)和短暂性脑缺血发作117例(45.3%)，从首次出现缺血事件到血管内介入治疗的平均时间为25.67 &#177; 21.01天。所有靶动脉粥样硬化性病变均经影像学检查证实，行颅脑MRA者66例(25.6%)，行颅脑CTA者158例(61.2%)，行颅脑DSA者201例(77.9%)。258名患者均成功完成血管内支架植入术，血运重建成功率达100%，平均狭窄程度从支架植入前的(83.73 &#177; 10.40%)降至术后的(8.5 &#177; 7.96%)。</p></sec><sec id="s7_2"><title>3.2. 两种类型的血管内治疗的基线特征比较</title><p>根据植入支架的类型将患者分为两组，134例患者接受球囊扩张支架治疗，124例接受自膨式支架治疗，基线特征见表1。比较两组患者的临床基线特征，包括年龄、性别、血管危险因素、缺血类型，均无统计学差异(P &gt; 0.05)。球囊扩张支架植入患者从缺血事件发生到支架植入时间为26.29 &#177; 20.99天，自膨式支架从缺血事件发生到支架植入时间为24.72 &#177; 21.25天，二者无统计学意义(P = 0.551)。球囊扩张支架组的平均狭窄程度为83.68 &#177; 10.23%，自膨式支架的平均狭窄程度为84.72 &#177; 7.59%，二者无统计学意义(P = 0.358)。与自膨式支架相比，球囊扩张支架更常应用于椎基底动脉狭窄，自膨式支架更常应用于大脑中动脉(P = 0.003)。MoriA病变患者主要采用球囊扩张支架进行治疗，而MoriC病变患者常采用自膨式支架治疗(P = 0.019)。应用自膨式支架的患者狭窄长度明显长于球囊扩张支架(8.69 &#177; 2.70 VS 7.32 &#177; 2.76 mm，P &lt; 0.001)。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of clinical characteristics between two types of endovascular therap</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" >使用球囊扩张支架患者(n = 134)</th><th align="center" valign="middle" >使用自膨式支架患者(n = 124)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >年龄(SD)</td><td align="center" valign="middle" >59.01 &#177; 8.75</td><td align="center" valign="middle" >56.77 &#177; 9.92</td><td align="center" valign="middle" >0.055</td></tr><tr><td align="center" valign="middle" >男性危险因素</td><td align="center" valign="middle" >100 (74.6%)</td><td align="center" valign="middle" >97 (78.2%)</td><td align="center" valign="middle" >0.497</td></tr><tr><td align="center" valign="middle" >高血压</td><td align="center" valign="middle" >101 (75.4%)</td><td align="center" valign="middle" >86 (69.4%)</td><td align="center" valign="middle" >0.280</td></tr><tr><td align="center" valign="middle" >高脂血症</td><td align="center" valign="middle" >58 (43.3%)</td><td align="center" valign="middle" >51 (41.1%)</td><td align="center" valign="middle" >0.726</td></tr><tr><td align="center" valign="middle" >糖尿病</td><td align="center" valign="middle" >40 (29.9%)</td><td align="center" valign="middle" >34 (27.4%)</td><td align="center" valign="middle" >0.666</td></tr><tr><td align="center" valign="middle" >吸烟史</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >目前吸烟</td><td align="center" valign="middle" >35 (26.1%)</td><td align="center" valign="middle" >32 (25.8%)</td><td align="center" valign="middle" >0.954</td></tr><tr><td align="center" valign="middle" >曾经吸烟已戒烟</td><td align="center" valign="middle" >39 (29.1%)</td><td align="center" valign="middle" >38 (30.6%)</td><td align="center" valign="middle" >0.787</td></tr><tr><td align="center" valign="middle" >从未吸烟</td><td align="center" valign="middle" >60 (44.8%)</td><td align="center" valign="middle" >54 (43.5%)</td><td align="center" valign="middle" >0.843</td></tr><tr><td align="center" valign="middle" >BMI(SD) (kg/㎡)</td><td align="center" valign="middle" >25.83 &#177; 3.18</td><td align="center" valign="middle" >25.47 &#177; 2.94</td><td align="center" valign="middle" >0.347</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >血压(SD)</th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >收缩压</td><td align="center" valign="middle" >137.2 &#177; 18.1</td><td align="center" valign="middle" >138.3 &#177; 18.3</td><td align="center" valign="middle" >0.628</td></tr><tr><td align="center" valign="middle" >舒张压</td><td align="center" valign="middle" >82.6 &#177; 11.0</td><td align="center" valign="middle" >83.2 &#177; 10.9</td><td align="center" valign="middle" >0.661</td></tr><tr><td align="center" valign="middle" >胆固醇</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >低密度脂蛋白</td><td align="center" valign="middle" >2.10 &#177; 0.98</td><td align="center" valign="middle" >2.29 &#177; 0.99</td><td align="center" valign="middle" >0.123</td></tr><tr><td align="center" valign="middle" >高密度脂蛋白</td><td align="center" valign="middle" >1.06 &#177; 0.31</td><td align="center" valign="middle" >1.09 &#177; 0.54</td><td align="center" valign="middle" >0.581</td></tr><tr><td align="center" valign="middle" >血糖</td><td align="center" valign="middle" >5.77 &#177; 1.95</td><td align="center" valign="middle" >6.09 &#177; 2.20</td><td align="center" valign="middle" >0.217</td></tr><tr><td align="center" valign="middle" >缺血事件</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.289</td></tr><tr><td align="center" valign="middle" >TIA</td><td align="center" valign="middle" >65 (48.5%)</td><td align="center" valign="middle" >52 (41.9%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >卒中</td><td align="center" valign="middle" >69 (51.5%)</td><td align="center" valign="middle" >72 (58.1%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >起病到治疗时间(SD)</td><td align="center" valign="middle" >26.29 &#177; 20.99</td><td align="center" valign="middle" >24.72 &#177; 21.25</td><td align="center" valign="middle" >0.551</td></tr><tr><td align="center" valign="middle" >狭窄位置</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.003</td></tr><tr><td align="center" valign="middle" >椎基底动脉</td><td align="center" valign="middle" >98 (73.1%)</td><td align="center" valign="middle" >69 (55.6%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >大脑中动脉</td><td align="center" valign="middle" >36 (34.3%)</td><td align="center" valign="middle" >55 (44.4%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >病变特点</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.019</td></tr><tr><td align="center" valign="middle" >Mori A</td><td align="center" valign="middle" >49 (36.6%)</td><td align="center" valign="middle" >29 (23.4%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >MoriB</td><td align="center" valign="middle" >68 (50.7%)</td><td align="center" valign="middle" >66 (53.2%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Mori C</td><td align="center" valign="middle" >17 (12.7%)</td><td align="center" valign="middle" >29 (23.4%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >大动脉平均狭窄程度(SD)</td><td align="center" valign="middle" >83.68 &#177; 10.23</td><td align="center" valign="middle" >84.72 &#177; 7.59</td><td align="center" valign="middle" >0.358</td></tr><tr><td align="center" valign="middle" >狭窄长度(SD)</td><td align="center" valign="middle" >7.32 &#177; 2.76</td><td align="center" valign="middle" >8.69 &#177; 2.70</td><td align="center" valign="middle" >0.000</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 两种血管内治疗方式的基线特征比较</p><p>BMI：Body Mass Index体质指数；TIA：transient cerebral ischemic attacks短暂性脑缺血发作。</p></sec><sec id="s7_3"><title>3.3. 两种类型的血管内治疗的临床特征比较</title><p>对两组血管内治疗的临床特征进行分析，结果发现自膨式支架治疗的患者接受全身麻醉的比例高于球囊扩张支架治疗的患者(81.5% VS 62.7%, P = 0.001)。使用自膨式支架的患者比球囊扩张支架的患者手术时间更长(93.53 &#177; 24.11 min VS 68.09 &#177; 16.74 min, P = 0.000)。此外，植入支架的长度也存在差异，即使用自膨式支架患者植入支架长度明显长于使用球囊扩张支架(14.44 &#177; 3.09 mm VS 9.67 &#177; 2.57 mm, P = 0.000)。自膨式支架植入支架的直径明显大于球囊扩张支架(3.06 &#177; 0.47 mm VS 2.69 &#177; 0.27 mm, P = 0.000)，使用自膨式支架的患者的残余狭窄程度高于球囊扩张支架(11.36 &#177; 8.26% VS 5.99 &#177; 6.48%, P = 0.000)。见表2。</p></sec><sec id="s7_4"><title>3.4. 两组血管内治疗的随访结果</title><p>治疗后1年共随访236例患者(91.5%)，结果发现，两组中使用自膨式支架的患者再狭窄发生率高(21/112 VS 11/124, P = 0.027)，且再狭窄程度也较球囊扩张支架高(48.5 &#177; 24.51% VS 36.2 &#177; 18.33, P &lt; 0.001)。球囊扩张支架的3例患者再狭窄程度 ≥ 50%，而自膨式支架的10例患者出现再狭窄 ≥ 50%，二者相比，有统计学意义(3/124 VS 10/112, P = 0.043)，即自膨式支架出现再狭窄 ≥ 50%要明显高于球囊扩张支架。球囊扩张支架的2名患者再狭窄程度达70%，与自膨式支架相比，无统计学意义(2/124 VS 5/112, P = 0.261)。两组出现缺血性卒中、出血性卒中、短暂性脑缺血发作、死亡的概率无显著差异(分别是P = 0.722、0.105、0.725、1.000)。两组之间发生任意缺血事件或死亡的总发生率的差异也无明显统计学意义(15/124 VS 14/112, P = 0.925)。最终的临床随访结果见表3。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of clinical characteristics between two types of endovascular therap</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" >使用球囊扩张支架患者(n = 134)</th><th align="center" valign="middle" >使用自膨式支架患者(n = 124)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >麻醉方式</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >局部麻醉</td><td align="center" valign="middle" >50 (37.3%)</td><td align="center" valign="middle" >23 (18.5%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >全身麻醉</td><td align="center" valign="middle" >84 (62.7%)</td><td align="center" valign="middle" >101 (81.5%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >手术时间，分钟(SD)</td><td align="center" valign="middle" >68.09 &#177; 16.74</td><td align="center" valign="middle" >93.53 &#177; 24.11</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >支架长度，毫米</td><td align="center" valign="middle" >9.67 &#177; 2.57</td><td align="center" valign="middle" >14.44 &#177; 3.09</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >支架直径，毫米</td><td align="center" valign="middle" >2.69 &#177; 0.27</td><td align="center" valign="middle" >3.06 &#177; 0.47</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >残余狭窄，%</td><td align="center" valign="middle" >5.99 &#177; 6.48</td><td align="center" valign="middle" >11.36 &#177; 8.26</td><td align="center" valign="middle" >0.000</td></tr></tbody></table></table-wrap><p>表2. 两种类型的血管内治疗的临床特征比较</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> One year follow-up results of endovascular treatment in two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >变量</th><th align="center" valign="middle"  colspan="2"  >使用球囊扩张支架患者(n = 124)</th><th align="center" valign="middle"  colspan="2"  >使用自膨式支架患者(n = 112)</th><th align="center" valign="middle"  rowspan="2"  >P值</th></tr></thead><tr><td align="center" valign="middle" >人数</td><td align="center" valign="middle" >平均值 &#177; 标准差OR%</td><td align="center" valign="middle" >人数</td><td align="center" valign="middle" >平均值 &#177; 标准差OR%</td></tr><tr><td align="center" valign="middle" >1年后再狭窄</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >8.21%</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >16.9%</td><td align="center" valign="middle" >0.027</td></tr><tr><td align="center" valign="middle" >再狭窄程度</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >36.2 &#177; 18.33</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >48.5 &#177; 24.51</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >再狭窄大于50%</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.42%</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >8.93%</td><td align="center" valign="middle" >0.043</td></tr><tr><td align="center" valign="middle" >再狭窄大于70%</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.61%</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >4.46%</td><td align="center" valign="middle" >0.261</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >缺血性卒中TIA</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >6.45%</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >5.36%</td><td align="center" valign="middle" >0.722</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >4.03%</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.68%</td><td align="center" valign="middle" >0.725</td></tr><tr><td align="center" valign="middle" >出血性卒中</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.68%</td><td align="center" valign="middle" >0.105</td></tr><tr><td align="center" valign="middle" >死亡</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.61%</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.79%</td><td align="center" valign="middle" >1</td></tr></tbody></table></table-wrap><p>表3. 两组血管内治疗的一年随访结果</p><p>由于基线特征比较，两组间血管位置比较存在统计学意义，加做了血管位置的预后，发现椎基底动脉与大脑中动脉再狭窄、缺血性卒中、出血性卒中、TIA、死亡发生率无明显统计学意义(P = 0.121、0.277、0.717、1.000)。见表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Comparison of prognosis between vertebrobasilar artery and middle cerebral arter</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" >椎基底动脉(n = 167)</th><th align="center" valign="middle" >大脑中动脉(n = 91)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >再狭窄(人)</td><td align="center" valign="middle" >17 (10.18%)</td><td align="center" valign="middle" >15 (16.48%)</td><td align="center" valign="middle" >0.121</td></tr><tr><td align="center" valign="middle" >缺血性卒中</td><td align="center" valign="middle" >11 (6.59%)</td><td align="center" valign="middle" >3 (3.29%)</td><td align="center" valign="middle" >0.390</td></tr><tr><td align="center" valign="middle" >出血性卒中</td><td align="center" valign="middle" >1 (0.59%)</td><td align="center" valign="middle" >2 (2.19%)</td><td align="center" valign="middle" >0.277</td></tr><tr><td align="center" valign="middle" >TIA</td><td align="center" valign="middle" >6 (3.59%)</td><td align="center" valign="middle" >2 (2.19%)</td><td align="center" valign="middle" >0.717</td></tr><tr><td align="center" valign="middle" >死亡</td><td align="center" valign="middle" >3 (1.79%)</td><td align="center" valign="middle" >1 (1.09%)</td><td align="center" valign="middle" >1.000</td></tr></tbody></table></table-wrap><p>表4. 椎基底动脉与大脑中动脉预后比较</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>近年来，球囊扩张支架(BMS)和自膨式支架(SES)用于治疗症状性颅内动脉狭窄，取得了良好的疗效 [<xref ref-type="bibr" rid="hanspub.41498-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.41498-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.41498-ref13">13</xref>]，在本研究中，支架植入术一年随访期后，出现安全事件的总发生率为12.28%，明显低于SAMMPRIS试验及VISSIT试验的终点事件发生率，且本研究纳入的患者均合并侧支循环不良，很难在药物治疗中得到良好的疗效 [<xref ref-type="bibr" rid="hanspub.41498-ref14">14</xref>]，这也证实了支架植入术的安全性及有效性。</p><p>近年来，由于SAMMPRIS研究及VISSIT研究存在局限性，使得支架治疗后的临床预后不佳，而本研究对其进行了改进，使得终点事件发生率明显低于SAMMPRIS试验及VISSIT试验。1) 在本研究中，患者入组标准更为严格，我们主要选择侧支循环欠佳，且血管狭窄程度重的患者(狭窄程度 &gt; 70%)，这些患者很难从药物治疗中受益 [<xref ref-type="bibr" rid="hanspub.41498-ref15">15</xref>]，且存在脑卒中复发的极大风险；2) 积极排除急性脑梗死的患者，有研究表明，最后一次缺血事件和手术之间的推荐时间间隔是三周 [<xref ref-type="bibr" rid="hanspub.41498-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.41498-ref16">16</xref>]，2019年也有研究提出14天内植入支架可能增加脑血管事件的发生风险 [<xref ref-type="bibr" rid="hanspub.41498-ref17">17</xref>]，严格的手术时机显得尤为重要，旨在保证斑块的稳定，极大限度地减少穿支卒中的发生 [<xref ref-type="bibr" rid="hanspub.41498-ref18">18</xref>]；3) 严格的围术期准备，本研究中的所有患者在手术前至少接受过5天阿司匹林和氯吡格雷双联抗血小板治疗，或服用负荷量氯吡格雷，这为术前积极的药物治疗提供了充足的时间，也为我们降低手术并发症的发生率提供了良好的条件；4) 研究的另外一个优点在于可供神经科医生根据患者血管情况选择不同的颅内支架；5) 手术医师丰富的支架植入经验也是必不可少的，本研究中进行支架植入术的医生都具有丰富的支架植入经验，这也为实现良好的临床结果打下了基础。</p><p>研究发现，使用自膨式支架的患者更容易接受全身麻醉(81.5% VS 62.7%, P = 0.001)，考虑可能是因为使用自膨式支架的患者手术时间更长，而影响手术时间的因素可能存在以下几个方面，使用自膨张支架的手术操作更复杂，球囊扩张支架植入步骤简易，可一步完成，而自膨式支架植入步骤较复杂，需球囊预扩张继而释放支架；应用自膨式支架的患者血管常较曲折，解剖结构更复杂，也相应增加了手术时间。</p><p>支架内再狭窄(In stent restenosis ISR)是影响颅内动脉支架植入术的主要原因，再狭窄即在先前支架区或邻近区域出现 &gt; 50%狭窄 [<xref ref-type="bibr" rid="hanspub.41498-ref19">19</xref>]，有研究表明，颅内动脉粥样硬化支架植入术后再狭窄与颅内动脉支架植入术后复发缺血事件的发生有明显相关性 [<xref ref-type="bibr" rid="hanspub.41498-ref20">20</xref>]。目前支架内再狭窄机制不明，考虑可能与血栓形成、内膜过度增生、血管重构相关 [<xref ref-type="bibr" rid="hanspub.41498-ref21">21</xref>]，内皮损伤和内皮功能失调以及新生内膜增殖是ISR发生的共同特征和基本机制。理论上来讲，球囊扩张支架的刚性及高充气压力更容易引起血管损伤、负性重构，使内皮损伤加剧，更易发生再狭窄，但是本研究发现相比于球囊扩张支架，自膨式支架的再狭窄率更高，原因可能有以下几个方面：1) 可能与自膨式支架的特点相关，有研究表明与自膨式支架的高柔韧性相关，使得动脉粥样硬化斑块容易向重塑血管的内部突出 [<xref ref-type="bibr" rid="hanspub.41498-ref22">22</xref>]；2) 自膨式支架残余狭窄程度高，有研究提出残余狭窄率高是再狭窄的危险因素之一 [<xref ref-type="bibr" rid="hanspub.41498-ref23">23</xref>]，球囊扩张支架可即刻扩张管径，迅速达到血管的再通，减少残余狭窄。本研究中球囊扩张支架的残余狭窄明显低于自膨式支架，恰恰降低了再狭窄的发生率，更有研究达到6月内再狭窄率为0%的奇迹 [<xref ref-type="bibr" rid="hanspub.41498-ref24">24</xref>]；3) 自膨式支架径向力小，很难达到血管的贴合，不能有效对抗血管的弹性回缩力，导致再狭窄的发生。</p><p>球囊扩张支架具有径向支撑力高，刚性强的特点，可明显降低残余狭窄，降低支架内再狭窄的风险，同时球囊扩张支架柔韧性差、弹性小，使得球囊扩张支架存在一定的局限性，1) 球囊扩张支架存在较高的径向支撑力，对血管壁压力大，容易造成血管的损伤，造成夹层、出血等风险；2) 球囊扩张支架直径选择不当会导致过度扩张或支架与血管壁的贴合不良 [<xref ref-type="bibr" rid="hanspub.41498-ref25">25</xref>] 目前可以通过亚最大球囊慢膨式血管成形术有效降低不良事件的发生 [<xref ref-type="bibr" rid="hanspub.41498-ref26">26</xref>]，而自膨式支架具有较低的径向力，所以对血管壁压力小，极大地降低了并发症的发生；3) 球囊扩张支架质地较硬，柔韧性差，很难通过曲折血管。研究发现球囊支架适用于动脉路径较直和Mori A型病变，自膨式支架适用于动脉路径迂曲、Mori C型病变或近端/远端节段之间直径明显不匹配的病变 [<xref ref-type="bibr" rid="hanspub.41498-ref16">16</xref>]，临床上通常根据病变血管的特点选择不同的支架；4) 球囊扩张支架通过球囊即时扩张狭窄血管，达到血管再通，球囊对动脉粥样硬化斑块产生挤压，引起斑块移位，容易出现穿支卒中，而自膨式支架的较小径向力降低了斑块的压缩力 [<xref ref-type="bibr" rid="hanspub.41498-ref27">27</xref>]，有效降低了穿支卒中的发生风险。2020年有研究提出球囊扩张支架多阶梯释放技术治疗颅内动脉粥样硬化性狭窄是可行的，可有效降低残余狭窄、穿支卒中、血管损伤的风险 [<xref ref-type="bibr" rid="hanspub.41498-ref28">28</xref>]，我们期望有更多随机对照研究出现，充分降低球囊扩张支架的局限性。</p><p>有研究发现，病变血管位置也能影响患者预后，有系统回顾的数据包括31项研究和1177例有症状的、高级别的颅内支架治疗，显示前循环的围手术期并发症发生率明显低于后循环(6.6 vs.12.1%, P &lt; 0.01)前循环发生并发症的风险较后循环低 [<xref ref-type="bibr" rid="hanspub.41498-ref22">22</xref>]，为了规避血管位置对本研究造成的偏倚，我们研究了本研究中椎基底动脉与大脑中动脉的预后，发现二者相比无明显统计学意义，这也进一步证实两组研究的可比性。</p><p>本研究发现在1年随访期间，两组随访结局无显著差异，多项研究发现球囊扩张支架和自膨式支架术后并发症发生率差异无统计学意义 [<xref ref-type="bibr" rid="hanspub.41498-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.41498-ref29">29</xref>]，本研究与以上研究结果不谋而合。球囊扩张支架与自膨式支架各具优势，两者长期预后无明显差异，临床上需针对不同的病变合理选择合适的支架类型。</p><p>本研究同时也存在一定的局限性，首先，该研究非随机双盲研究，存在一定偏倚，即手术者的支架选择存在偏好；其次，该研究虽然是全国多中心研究，但手术者的技术也存在一定的差异。因此我们期待更多随机、双盲的大型临床试验展开，为支架研究提供更多的循证学依据。</p><p>对于有严重颅内动脉狭窄且合并侧支循环不良的患者，支架治疗可能预后更好，不良事件发生率更低。在本研究中，球囊扩张支架较自膨式支架发生再狭窄的机率及再狭窄程度均低，但其1年内随访结果无明显差异。</p></sec><sec id="s9"><title>利益冲突</title><p>本文无利益冲突。</p></sec><sec id="s10"><title>同意书</title><p>参与研究患者均签署知情同意书，不侵犯患者利益，符合伦理委员会要求，已通过伦理许可。</p></sec><sec id="s11"><title>文章引用</title><p>丁鸿斐,滕文慧,付 蕾,张贤军,荣 婷,姜 英,张 勇,王乃东. 球囊扩张支架与自膨式支架治疗侧支循环欠佳的症状性颅内动脉狭窄的临床研究Balloon-Mounted Stent versus Self-Expanding Stent for Symptomatic Intracranial Artery Stenosis Combined with Poor Collateral Circulation[J]. 临床医学进展, 2021, 11(04): 1473-1481. https://doi.org/10.12677/ACM.2021.114211</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41498-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, M., Wang, H., Zeng, X., et al. (2019) Mortality, Morbidity, and Risk Factors in China and Its Provinces, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet, 394, 1145-1158.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(19)30427-1</mixed-citation></ref><ref id="hanspub.41498-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Holmstedt, C.A., Turan, T.N. and Chimowitz, M.I. (2013) Atherosclerotic Intracranial Arterial Stenosis: Risk Factors, Diagnosis, and Treatment. The Lancet Neurology, 12, 1106-1114. &lt;br&gt;https://doi.org/10.1016/S1474-4422(13)70195-9</mixed-citation></ref><ref id="hanspub.41498-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Kasner, S.E., Lynn, M.J., Chimowitz, M.I., et al. (2006) Warfarin vs Aspirin for Symptomatic Intracranial Stenosis: Subgroup Analyses from WASID. Neurology, 67, 1275-1278. &lt;br&gt;https://doi.org/10.1212/01.wnl.0000238506.76873.2f</mixed-citation></ref><ref id="hanspub.41498-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Li, T.X., Gao, B.L., Cai, D.Y., et al. (2015) Wingspan Stenting for Severe Symptomatic Intracranial Atherosclerotic Stenosis in 433 Patients Treated at a Single Medical Center. PLoS One, 10, e0139377.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0139377</mixed-citation></ref><ref id="hanspub.41498-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Tang, C.-W., Chang, F.-C., Chern, C.-M., Lee, Y.-C., Hu, H.-H. and Lee, I.-H. (2011) Stenting versus Medical Treatment for Severe Symptomatic Intracranial Stenosis. American Journal of Neuroradiology, 32, 911-916.  
&lt;br&gt;https://doi.org/10.3174/ajnr.A2409</mixed-citation></ref><ref id="hanspub.41498-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Alexander, M.J., Zauner, A., Chaloupka, J.C., et al. (2019) WEAVE Trial: Final Results in 152 On-Label Patients. Stroke, 50, 889-894. &lt;br&gt;https://doi.org/10.1161/STROKEAHA.118.023996</mixed-citation></ref><ref id="hanspub.41498-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Yu, S.C., Leung, T.W.H., Hung, E.H.Y., Lee, K.T. and Wong, L.K.S. (2012) Angioplasty and Stenting for Intracranial Atherosclerotic Stenosis with Nitinol Stent: Factors Affecting Technical Success and Patient Safety. Operative Neurosurgery, 70, 104-113. &lt;br&gt;https://doi.org/10.1227/NEU.0b013e3182320bb0</mixed-citation></ref><ref id="hanspub.41498-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Maier, I.L., Karch, A., Lipke, C., et al. (2018) Transluminal Angioplasty and Stenting versus Conservative Treatment in Patients with Symptomatic Basilar Artery Stenosis: Perspective for Future Clinical Trials. Clinical Neuroradiology, 28, 33-38. &lt;br&gt;https://doi.org/10.1007/s00062-016-0528-x</mixed-citation></ref><ref id="hanspub.41498-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Gao, P., Wang, D., Zhao, Z., et al. (2016) Multicenter Prospective Trial of Stent Placement in Patients with Symptomatic High-Grade Intracranial Stenosis. American Journal of Neuroradiology, 37, 1275-1280.  
&lt;br&gt;https://doi.org/10.3174/ajnr.A4698</mixed-citation></ref><ref id="hanspub.41498-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">李宝民, 缪中荣, 王拥军, 徐安定, 曾进胜. 症状性颅内动脉粥样硬化性狭窄血管内治疗中国专家共识2018 [J]. 中国卒中杂志, 2018, 13(6): 594-604.</mixed-citation></ref><ref id="hanspub.41498-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Yue, X., Yin, Q., Xi, G., et al. (2011) Comparison of BMSs with SES for Symptomatic Intracranial Disease of the Middle Cerebral Artery Stenosis. CardioVascular and Interventional Radiology, 34, 54-60.  
&lt;br&gt;https://doi.org/10.1007/s00270-010-9885-z</mixed-citation></ref><ref id="hanspub.41498-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Y., Rajah, G.B., Liu, P., et al. (2019) Balloon-Mounted versus Self-Expanding Stents for Symptomatic Intracranial Vertebrobasilar Artery Stenosis Combined with Poor Collaterals. Neurological Research, 41, 704-713.  
&lt;br&gt;https://doi.org/10.1080/01616412.2019.1610837</mixed-citation></ref><ref id="hanspub.41498-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Li, G., Wang, N., Li, X., et al. (2019) Balloon-Mounted versus Self-Expanding Stent Outcomes in Symptomatic Middle Cerebral Artery Stenosis Combined with Poor Collaterals in China: A Multicenter Registry Study. World Neurosurgery, 124, e675-e681. &lt;br&gt;https://doi.org/10.1016/j.wneu.2018.12.189</mixed-citation></ref><ref id="hanspub.41498-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Miao, Z., Zhang, Y., Shuai, J., et al. (2015) Thirty-Day Outcome of a Multicenter Registry Study of Stenting for Symptomatic Intracranial Artery Stenosis in China. Stroke, 46, 2822-2829.  
&lt;br&gt;https://doi.org/10.1161/STROKEAHA.115.010549</mixed-citation></ref><ref id="hanspub.41498-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Abe, A., Ueda, T., Ueda, M., et al. (2012) Symptomatic Middle Cerebral Artery Stenosis Treated by Percutaneous Transluminal Angioplasty: Improvement of Cerebrovascular Reserves. Interventional Neuroradiology, 18, 213-220.  
&lt;br&gt;https://doi.org/10.1177/159101991201800215</mixed-citation></ref><ref id="hanspub.41498-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Miao, Z., Song, L., Liebeskind, D.S., et al. (2015) Outcomes of Tailored Angioplasty and/or Stenting for Symptomatic Intracranial Atherosclerosis: A Prospective Cohort Study after SAMMPRIS. Journal of NeuroInterventional Surgery, 7, 331-335. &lt;br&gt;https://doi.org/10.1136/neurintsurg-2014-011109</mixed-citation></ref><ref id="hanspub.41498-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Y., Sun, Y., Li, X., et al. (2020) Early versus Delayed Stenting for Intracranial Atherosclerotic Artery Stenosis with Ischemic Stroke. Journal of NeuroInterventional Surgery, 12, 274-278.  
&lt;br&gt;https://doi.org/10.1136/neurintsurg-2019-015035</mixed-citation></ref><ref id="hanspub.41498-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Miao, Z. (2014) Intracranial Angioplasty and Stenting before and after SAMMPRIS: “From Simple to Complex Strategy—The Chinese Experience”. Frontiers in Neurology, 5, 129. &lt;br&gt;https://doi.org/10.3389/fneur.2014.00129</mixed-citation></ref><ref id="hanspub.41498-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Cassese, S., Byrne, R.A., Tada, T., et al. (2014) Incidence and Predictors of Restenosis after Coronary Stenting in 10004 Patients with Surveillance Angiography. Heart, 100, 153-159. &lt;br&gt;https://doi.org/10.1136/heartjnl-2013-304933</mixed-citation></ref><ref id="hanspub.41498-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Jin, M., Fu, X., Wei, Y.Z., Du, B., Xu, X.T. and Jiang, W.J. (2013) Higher Risk of Recurrent Ischemic Events in Patients with Intracranial In-Stent Restenosis. Stroke, 44, 2990-2994. &lt;br&gt;https://doi.org/10.1161/STROKEAHA.113.001824</mixed-citation></ref><ref id="hanspub.41498-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Mitra, A.K. and Agrawal, D.K. (2006) In Stent Restenosis: Bane of the Stent Era. Journal of Clinical Pathology, 59, 232-239. &lt;br&gt;https://doi.org/10.1136/jcp.2005.025742</mixed-citation></ref><ref id="hanspub.41498-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Groschel, K., Schnaudigel, S., Pilgram, S.M., Wasser, K. and Kastrup, A. (2009) A Systematic Review on Outcome after Stenting for Intracranial Atherosclerosis. Stroke, 40, e340-e347.  
&lt;br&gt;https://doi.org/10.1161/STROKEAHA.108.532713</mixed-citation></ref><ref id="hanspub.41498-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Sick, P., Hüttl, T., Niebauer, J., et al. (2003) Influence of Residual Stenosis after Percutaneous Coronary Intervention with Stent Implantation on Development of Restenosis and Stent Thrombosis. The American Journal of Cardiology, 91, 148-153. &lt;br&gt;https://doi.org/10.1016/S0002-9149(02)03100-4</mixed-citation></ref><ref id="hanspub.41498-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Suh, D.C., Kim, J.K., Choi, J.W., et al. (2008) Intracranial Stenting of Severe Symptomatic Intracranial Stenosis: Results of 100 Consecutive Patients. American Journal of Neuroradiology, 29, 781-785.  
&lt;br&gt;https://doi.org/10.3174/ajnr.A0922</mixed-citation></ref><ref id="hanspub.41498-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Hartmann, M. and Jansen, O. (2005) Angioplasty and Stenting of Intracranial Stenosis. Current Opinion in Neurology, 18, 39-45. &lt;br&gt;https://doi.org/10.1097/00019052-200502000-00009</mixed-citation></ref><ref id="hanspub.41498-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Connors 3rd, J.J. and Wojak, J.C. (1999) Percutaneous Transluminal Angioplasty for Intracranial Atherosclerotic Lesions: Evolution of Technique and Short-Term Results. Journal of Neurosurgery, 91, 415-423.  
&lt;br&gt;https://doi.org/10.3171/jns.1999.91.3.0415</mixed-citation></ref><ref id="hanspub.41498-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Bose, A., Hartmann, M., Henkes, H., et al. (2007) A Novel, Self-Expanding, Nitinol Stent in Medically Refractory Intracranial Atherosclerotic Stenoses: The Wingspan Study. Stroke, 38, 1531-1537.  
&lt;br&gt;https://doi.org/10.1161/STROKEAHA.106.477711</mixed-citation></ref><ref id="hanspub.41498-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">王云, 王连芹, 李英毅, 等. 球囊扩张支架多梯次压力释放在症状性颅内动脉粥样硬化性狭窄中的疗效分析[J]. 中国脑血管病杂志, 2020, 17(3): 117-125.</mixed-citation></ref><ref id="hanspub.41498-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">童晨光, 李慎茂, 缪中荣, 焦力群, 朱凤水. 球囊扩张支架与自膨式支架治疗症状性颅内动脉重度狭窄的比较[J]. 中国脑血管病杂志, 2011, 8(1): 13-17.</mixed-citation></ref></ref-list></back></article>